Hims surpassed 2.4 million subscribers with 95% recurring revenue and over 85% retention, driving 111% YoY revenue growth. Average monthly revenue per subscriber rose 50% YoY, showing strong monetization through personalization, bundling, and chronic care expansion. Despite Novo deal fallout, Hims continues scaling GLP-1 offerings and accelerating proprietary semaglutide development amid regulatory scrutiny.
Hims & Hers Health (HIMS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Household & Personal Products Industry | Consumer Defensive Sector | Andrew Dudum CEO | NYSE Exchange | 433000106 Cusip |
US Country | 1,637 Employees | - Last Dividend | - Last Split | 13 Sep 2019 IPO Date |
Hims & Hers Health, Inc., based in San Francisco, California, operates as a telehealth platform connecting consumers with licensed healthcare professionals across the United States, the United Kingdom, and other international locations. The company leverages its websites and mobile application to offer a variety of carefully selected health and wellness products and services, both on prescription and over-the-counter basis. Its business model focuses on providing convenient access to ongoing healthcare services, including prescription medication refills and consultations with healthcare providers, as well as a wide range of wellness products through direct sales and wholesale partnerships.